SEATTLE,
April 14, 2009 - Dendreon Corporation (Nasdaq:
DNDN)
announced today that the pivotal Phase 3 IMPACT
study of PROVENGE®
(sipuleucel-T) in men with advanced prostate
cancer met its primary
endpoint of improving overall survival compared
to a placebo control. The
magnitude of the survival difference observed in
the intent to treat
population resulted in the study successfully
achieving the pre-specified
level of statistical significance defined by the
study's design. The
safety profile of PROVENGE appeared to be
consistent with prior trials.
